Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
The EyePoint, Inc. (EYPT) news page on Stock Titan aggregates company-reported updates and market-moving announcements for this clinical-stage biopharmaceutical business focused on serious retinal diseases. EyePoint’s disclosures emphasize its lead investigational product, DURAVYU™ (vorolanib intravitreal insert), and its progress through late-stage clinical development, making corporate news particularly relevant for investors tracking ophthalmology and retinal therapeutics.
Visitors can review news covering clinical milestones, such as enrollment completion and data safety monitoring committee recommendations for the Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration (wet AMD), as well as the design and initiation of the pivotal Phase 3 COMO and CAPRI trials in diabetic macular edema (DME). Company releases also highlight Phase 2 data from the DAVIO 2 and VERONA studies, which EyePoint cites as demonstrating meaningful and sustained improvements in vision and anatomy with favorable safety profiles.
In addition to clinical trial updates, EyePoint’s news includes financing and corporate developments, such as underwritten public offerings, at-the-market equity programs, and inducement grants under Nasdaq Listing Rule 5635(c)(4). These items provide context on how the company funds its DURAVYU programs and earlier-stage pipeline initiatives. Investors can also follow announcements about conference presentations at major healthcare and ophthalmology meetings and investor conferences, where EyePoint discusses its clinical data, trial designs, and development strategy.
By monitoring the EYPT news feed, readers can see how EyePoint communicates progress on its investigational sustained-delivery approach, interactions with regulators, and key risk disclosures referenced in forward-looking statements. This page is useful for those who want a centralized view of EyePoint’s official announcements, ranging from clinical milestones and safety updates to capital-raising activities and corporate governance events.
Summary not available.
Summary not available.
Summary not available.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced a conference call and live webcast set for May 3, 2023, at 8:30 a.m. ET to report its first-quarter 2023 financial results and discuss recent corporate developments. The event will provide investors an opportunity to gain insights into the company's performance and strategic initiatives. EyePoint is focused on developing therapeutics for serious eye disorders, leveraging its proprietary Durasert technology for sustained drug delivery. Among its pipeline products is EYP-1901, currently in Phase 2 clinical trials, which targets intravitreal anti-VEGF treatment. EyePoint’s products, including YUTIQ, have previously gained FDA approval, showcasing its commitment to advancing eye care solutions.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced on April 17, 2023, the grant of non-statutory stock options for 13,000 shares to two new employees as part of an inducement package outside its 2016 Long-Term Incentive Plan. The options were granted on April 14, 2023, with an exercise price set at $4.33 per share, reflecting the stock’s closing price on that date. The options have a ten-year term and vest over four years, beginning with 25% vesting after one year, followed by monthly vesting thereafter. This move is in accordance with NASDAQ Listing Rule 5635(c)(4) and aims to enhance recruitment efforts by offering competitive compensation packages to new talent.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has successfully completed enrollment in its Phase 2 clinical trial, DAVIO 2, evaluating EYP-1901 for wet age-related macular degeneration (AMD). The trial exceeded its goal by enrolling 160 patients, with top-line data expected in Q4 2023. EYP-1901 aims to provide a six-month maintenance treatment option, addressing the significant treatment burden faced by wet AMD patients. The drug leverages EyePoint's Durasert technology for sustained delivery and has shown promising Phase 1 results, including a stable safety profile and visual acuity.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced positive scientific findings to be presented at the 2023 ARVO Annual Meeting. Key highlights include the neuroprotective effect of vorolanib in EYP-1901, demonstrating potential against retinal degeneration in a validated model. Additionally, findings from the CALM registry indicate effective control of inflammation in chronic posterior segment uveitis using YUTIQ. Presentations will cover preclinical data and clinical outcomes, including the Phase 1 DAVIO trial results showing a significant reduction in the need for anti-VEGF injections. The meeting takes place from April 23-27, 2023, in New Orleans.
EyePoint Pharmaceuticals announced its financial results for 2022, reporting a 13% increase in net product revenues to $39.9 million. The company has two Phase 2 clinical trials in progress for EYP-1901, targeting wet AMD and NPDR, with topline data expected by year-end 2023. In addition, operating expenses rose to $141 million, primarily due to a $20.7 million impairment charge from DEXYCU. EyePoint has $144.6 million in cash and investments, projected to fund operations into 2H 2024. The company also plans to disclose preclinical data at the upcoming 2023 ARVO Annual Meeting.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), based in Watertown, Mass., announced participation in two upcoming conferences. The Cowen 43rd Annual Healthcare Conference will feature a fireside chat on March 6, 2023, at 9:10 a.m. ET. The Guggenheim 4th Annual Healthy Altitudes Summit is scheduled for March 15, 2023, at 9:00 a.m. ET. Investors can access webcasts and archived replays via the company’s website. EyePoint specializes in developing therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained drug delivery, including the investigational EYP-1901, currently in Phase 2 trials.
EyePoint Pharmaceuticals (NASDAQ: EYPT) and Rallybio Corporation have announced a research collaboration focused on the sustained delivery of Rallybio's complement component 5 (C5) inhibitor using EyePoint's Durasert technology. This partnership aims to develop a long-acting treatment for geographic atrophy, an advanced form of age-related macular degeneration leading to vision loss. EyePoint's Durasert technology offers a potential alternative to existing therapies, requiring less frequent injections. Approximately 1 million people in the U.S. are affected by geographic atrophy, highlighting the significant unmet medical need for effective treatments.